Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
The most recent EPS for Takeda Pharmaceutical Company Limited is $65.64, beating expectations of $34.44.
How did Takeda Pharmaceutical Company Limited TAK's revenue perform in the last quarter?
Takeda Pharmaceutical Company Limited revenue for the last quarter is $65.64
What is the revenue estimate for Takeda Pharmaceutical Company Limited?
According to 8 of Wall street analyst, the revenue estimate of Takeda Pharmaceutical Company Limited range from $1195.55B to $1087.6B
What's the earning quality score for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Takeda Pharmaceutical Company Limited report earnings?
Takeda Pharmaceutical Company Limited next earnings report is expected in 2026-04-30
What are Takeda Pharmaceutical Company Limited's expected earnings?
Takeda Pharmaceutical Company Limited expected earnings is $1189.19B, according to wall-street analysts.
Did Takeda Pharmaceutical Company Limited beat earnings expectations?
Takeda Pharmaceutical Company Limited recent earnings of $1191.69B beat expectations.